20/20 Biolabs (NASDAQ:AIDX) Issues Earnings Results

20/20 Biolabs (NASDAQ:AIDX) issued its earnings results on Friday. The company reported ($0.26) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.73 million for the quarter.

20/20 Biolabs Stock Up 5.9%

Shares of NASDAQ AIDX traded up $0.03 during midday trading on Friday, reaching $0.55. 228,359 shares of the stock were exchanged, compared to its average volume of 532,094. 20/20 Biolabs has a 12 month low of $0.40 and a 12 month high of $50.00. The stock has a market capitalization of $6.73 million and a P/E ratio of -1.96. The business’s 50-day moving average is $0.58.

Wall Street Analysts Forecast Growth

Several analysts have commented on AIDX shares. Maxim Group assumed coverage on shares of 20/20 Biolabs in a research report on Monday, May 11th. They set a “buy” rating and a $5.00 target price for the company. Weiss Ratings upgraded 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $5.00.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.